tbuckley/cabot-search huggingface dataset:
Abstract P6-08-04: AP-1 Activation and a Functional SNP242 Regulate the LY-6K Gene Expression in Human Breast Cancer Cells
Authors: HK Kong, JH Park
Journal: Cancer Research (2010)

Abstract Background: Lymphocyte antigen 6 complex locus K(LY-6K), a member of cancer-testis antigen, is a novel breast cancer biomarker. Elevated LY-6K induces cell invasion and metastasis through activating the Raf-1/MEK/ERK signaling pathway. And in a previous study, breast cancer patients have single nucleotide polymorphism (SNP) within promoter of LY-6K. However, the molecular mechanisms that mediate regulation of human LY-6K gene expression are completely unknown. Material and Methods: The human breast carcinoma cells used in these studies include the MCF7 and adriamycin resistant MCF7. Within the pGL3 reporter vector, the -3050/+182 bp fragment and truncated fragment (deleted from -500 to -1 bp and from -1550 to -1050 bp) upstream of the LY-6K gene was subcloned and measured promoter activity. Next, multiple cis elements were identified using several gene tool software (TFSEARCH, TRANSFAC, PROMO and MATCHTM) in the promoter of human LY-6K gene. Substitution of two base pair of transcription factor binding site or single base pair of SNP was subcloned within pGL3 vector using site-directed mutagenesis and measured transcriptional activity. Chromatin immunoprecipitation (ChIP), electrophoretic mobility shift assay (EMSA) and supershift assays were used to demonstrate in vitro interactions between the transcription factor and transcription factor binding site within the promoter of LY-6K. Results: We found that a novel AP-1 binding site in the LY-6K promoter. The substitution from C to G at the 242 nucleotide position in the promoter region is a functional LY-6K single nucleotide polymorphism (called SNP242), which increase AP-1 transcription binding affinity to LY-6K promoter. Ongoing studies are investigating to identify the relationship between LY-6K transcription and SNP756 which located at the 756 nucleotide position within LY-6K promoter and to find binding partner of LY-6K. We are also manipulating LY-6K transgenic mouse and knock-out mouse to investigate the mechanism of LY-6K in vivo. Discussion: The activity of the AP-1 transcription factor plays an important role in cell mobility of breast cancer cells via the promoting of LY-6K gene expression. LY-6K expression is dependent on not AP-1 transcription factor, but also SNP242 G allele by increasing AP-1 binding affinity. We demonstrated that metastasis of breast cancer cells depend on LY-6K expression turn on ERK signaling. These results suggested that LY-6K SNP242 G allele increases the risk of cancer and metastasis and LY-6K communicate with integrin-GPCR to cell migration via activating Ras/ERK signaling pathway. Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P6-08-04.
15. Diabetes Care in the Hospital: <i>Standards of Medical Care in Diabetes—2021</i>
Journal: Diabetes Care (2020)

The American Diabetes Association (ADA) "Standards of Medical Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee (https://doi.org/10.2337/dc21-SPPC), are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations, please refer to the Standards of Care Introduction (https://doi.org/10.2337/dc21-SINT). Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
AIDS Clinical Trials Information Service
Journal: JAMA (1991)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Diagnosing myiasis
Authors: N. Guillozet
Journal: JAMA (1980)

Misdiagnosis of cutaneous myiasis results in incorrect treatment, anxiety, and excessive scarring. In both temperate and tropical zones, the larvae of a variety of Diptera flies with different reproductive patterns are responsible for myiatic skin conditions and other symptoms. Suspicion of myiasis in the presence of an unhealing insect bite or furuncle can lead to prompt, simple, and effective treatment. (<i>JAMA</i>244:698-699, 1980)
Inhibition of experimentally induced cirrhosis in rats by hypothyroidism
Authors: R Oren, I Dotan, M Papa, Y Marravi, H Aeed, J Barg, L Zeidel, R Bruck, Z Halpern
Journal: Hepatology (1996)

The coexistence of hyperkinetic circulation, hypermetabolism, and hyperactivity of the sympathetic nervous system is encountered in both cirrhosis and hyperthyroidism. Several drugs, such as propylthiouracil and propranolol, that are beneficial for treating some patients with chronic liver diseases are also prescribed for the treatment of thyrotoxicosis. We investigated the effects of experimentally induced hypo– and hyperthyroidism on the development of cirrhosis induced in rats by thioacetamide (TAA). We specifically examined whether hypothyroidism could prevent and hyperthyroidism could aggravate liver damage. Hypothyroidism induced by methimazole (MMI, 0.04%), propylthiouracil (PTU 0.05%), and by thyroidectomy was confirmed by a significant elevation of thyroid–stimulating hormone (TSH) levels. Hyperthyroidism (decreased TSH levels) was induced by eltroxin (ELT: 50 micrograms/kg). Thirteen groups of 10 rats each were studied: euthyroid controls (3 groups: water, TAA 1.5 months, and TAA 3 months), hypothyroid (6 groups: MMI, PTU, surgical, MMI–TAA, PTU–TAA, surgical–TAA), and hyperthyroid (4 groups:ELT 1.5 months and 3 months, and ELT–TAA for 1.5 months and 3 months). Hepatic fibrosis (scored from 0 to 3) was significantly reduced ( P &lt; .0001) in hypothyroid rats as compared with euthyroid controls, and was aggravated in TAA–treated hyperthyroid rats ( P &lt; .0001). Quantitative microscopic analysis of liver biopsy specimens from all groups confirmed the semiquantitative histopathological scores ( P &lt; .001). Direct intrasplenic pressure measurement revealed a significant portal pressure elevation in the TAA and the ELT–treated rats (from 4.7 ± 0.1 in the euthyroid group to 8.1 ± 2.3 and 10.2 ± 2.1 and 12.5 ± 1.6 in the TAA, ELT and ELT– TAA groups, respectively). However, in the hypothyroid–TAA groups, the portal pressure was found to be within the euthyroid normal range (4.6 ± 1.2 and 5.8 ± 0.6 in the PTU–TAA and surgical–TAA, respectively). After 12 weeks, the mean spleen weight of rats receiving only TAA was significantly higher than the TAA–treated hypothyroid rats ( P &lt; .0001), indicating that the hypothyroid TAA–treated rats were less portal hypertensive. These results suggest that induced hypothyroidism can inhibit, whereas hyperthyroidism can aggravate, the development of cirrhosis in a rat model.
Polymorphonuclear function in Behcet's syndrome.
Authors: C Friman, P Davis
Journal: Annals of the Rheumatic Diseases (1983)

Septic arthritis due to Bacteroides fragilis SIR, We read with interest the report of Hart et al. ' of a case ofBacteroides fragilis septic arthritis of the wrist in a patient with rheumatoid arthritis (RA).They made the claim that this was probably the first case report of wrist joint involve- ment due to this organism.By coincidence we reported a similar case of septic polyarthritis due to Bacteroides fragilis in a patient with RA earlier in 1982.'This patient had bacteroides sepsis in 9 joints including both wrists, and also responded well to metronidazole treatment.A joint infection in a patient with RA should not only be considered when one joint suddenly flares up, but should also be borne in mind with a generalised flare-up, and anaerobic cultures should be done after joint aspirations as a routine investigation.
Dietary sources of long-chain n-3 polyunsaturated fatty acids
Authors: E. N. Siguel
Journal: JAMA (1996)

<h3>In Reply.</h3> —We welcome the opportunity to respond to Drs Reidenberg, Twycross, Lickiss, Ventafridda, and Stjernsward in relation to our article on the WHO analgesic ladder. None of the letters contradict our analysis of the published literature. The two major concerns are that we ignored the importance of the ladder as a political tool and that the benefits of the ladder are so obvious that rigorous randomized control trials are not needed. We endorse all efforts made by the WHO program to increase the availability and acceptability of opioids for the treatment of cancer pain throughout the world, and share Dr Reidenberg's concerns about the limited implementation of the ladder. The focus of our review, however, was not to evaluate the political utility of the ladder, but to assess the evidence on the effectiveness of the ladder when it is used. We acknowledge the difficulties in conducting rigorously controlled studies
Sickle cell anemia and iron deficiency
Authors: M. H. Steinberg
Journal: JAMA (1982)

<h3>To the Editor.—</h3> I would take issue with some of the evidence and the conclusions reached in the recent article on the interaction of sickle cell anemia (SCA) and iron deficiency by Natta et al (1982;247:1442) and the accompanying editorial by Nalbandian (1982;247:1462). While the patient described by Natta and co-workers has clearly become iron deficient, the data reported by no means establish the etiology as being due to iron loss in urine. Iron deficiency developing from the reported level of urine iron excretion is very unlikely. A yearly urinary loss of about 300 mg of iron would occur, but the patient received at least 10 g of iron via transfusion. Since iron deficiency appeared to develop between ages 19 and 22 years, and as it would take at least 25 to 30 years to lose the transfused iron by the reported rate of urinary excretion, it is very likely
Brainbridge and Menzies Essentials of Physiology.
Journal: JAMA (1926)

This edition, edited and revised by Professor Evans, does not differ in any essential from the fourth edition, which appeared in 1920. If there are any changes (aside from the description of the action of insulin) they are hard to detect. Some illustrations have been omitted; others, added. The size of the volume remains the same. The book is too advanced for use in courses of college physiology; besides, it lacks anatomic and biochemical data essential for an elementary textbook. It is too abbreviated for use by medical students. Whether it answers the purpose for which it was written—to meet "the requirements of the medical student preparing for a pass examination in the subject of physiology"—is hard to tell. It seems to us that a student can accomplish more if, in his attempt to review his physiology on short notice, he glances through the textbook he originally used, rather than
Highlights
Journal: JAMA (2018)

Prophylactic hypothermia may attenuate infl ammatory and biochemical cascades to limit secondary brain injury.For the POLAR Trial Investigators and the ANZICS Clinical Trials Group, Cooper and colleagues randomized 511 patients with severe traumatic brain injury and found that early prophylactic hypothermia compared with normothermia did not improve neurologic outcomes.In an Editorial, Docherty and colleagues discuss why clinical trials of this intervention have not been successful, despite the promising fi ndings of animal studies.
Limitations of Serum Electrophoresis in Dermatologic Diseases
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Laboratory tests: misuse and abuse
Journal: JAMA (1971)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Aspirin-induced prolongation of bleeding time and perioperative blood loss
Authors: P. C. Amrein
Journal: JAMA (1981)

One hundred twenty-nine patients undergoing total hip replacement were treated with aspirin at a level of either 300 mg four times a day (1.2 g/day) or 900 mg four times a day (3.6 g/day). Baseline bleeding times before aspirin treatment averaged 4.18±1.44 minutes. Two hours after 300 mg and 900 mg of aspirin, the bleeding times were 5.83±1.88 and 5.72±1.57 minutes, respectively. After three to five days of aspirin therapy at 1.2 g/day and 3.6 g/day, the bleeding times were 6.27±2.27 and 6.43±2.11 minutes, respectively. The bleeding times for all the aspirin-treated groups were longer than baseline times. No paradoxical shortening of the bleeding time was noted at the 3.6-g/day dose. Perioperative blood loss for those receiving aspirin was not increased in six of eight subsets by operation and anesthesia when compared with historical control subjects. Neither a bleeding time greater than ten minutes nor a prolongation of the bleeding time by aspirin of more than four minutes over baseline bleeding times was associated with increased perioperative blood loss. (<i>JAMA</i>1981;245:1825-1828)
Phase II study of maintenance therapy with temsirolimus (TEM) after response to first-line docetaxel (TAX) chemotherapy in castration-resistant prostate cancer (CRPC).
Authors: U. Emmenegger, S. R. Berry, C. Booth, S. S. Sridhar, E. Winquist, N. Bandali, A. Chow, R. S. Kerbel, Y. Ko
Journal: Journal of Clinical Oncology (2011)

160 Background: TAX is the standard first-line chemotherapy for CRPC. However, a number of questions remain regarding the optimal use of TAX following maximal response. Aside from intermittent TAX, maintenance therapy with well-tolerated agents such as the mTOR inhibitor TEM could be one strategy to prolong treatment response and the chemotherapy-free interval, without significantly compromising quality of life. In fact, the mTOR pathway is involved in many aspects of CRPC, and mTOR inhibitors have demonstrated significant anti-CRPC activity in preclinical testing. Methods: CRPC pts eligible for this single-arm, multicenter phase II trial must have received between 6 to 8 cycles of first-line TAX (75 mg/m2 q3wks) with documented treatment response by PSA (&gt;50% decline from baseline) or RECIST criteria. 30 pts will be enrolled and administered weekly TEM (25 mg iv × 4/cycle). The primary endpoint is time to treatment failure (TTF, by RECIST or symptomatic progression). Secondary endpoints include safety (NCI-CTCAE v3.0), quality of life (FACT-P, PPI), changes in PSA doubling time and time to PSA progression, objective tumor response rate (RECIST), and overall survival. We will also study correlative endpoints using plasma and peripheral blood mononuclear cells (i.e., markers of mTOR inhibition, of antiangiogenic TEM effects and of intratumoral hypoxia/acidosis, the latter as potential predictive markers). Results: 10 pts have been enrolled to date: mean age 68 (range 52-80), prior definitive local therapy (7)—radiation (6), prostatectomy (1), mean PSA at entry 99.28 (2.3- 380.7), ECOG 0 (4) or 1 (6), prior cycles of TAX 6 (6) or 8 (4), sites of metastasis—bone (8), lymph nodes (4), visceral (3). 6 pts have been discontinued due to treatment failure after a mean of 5.3±1.9 cycles (range 3-8) - RECIST (1), symptomatic (2), combined (3). 4 pts are on cycle 1-2-8-9, respectively. TEM has been generally well tolerated without unexpected side-effects, but may have contributed to worsening lymphedema in 1 pt. Conclusions: TEM maintenance therapy in CRPC pts that have responded to first-line TAX is well tolerated and appears to result in meaningful TTF. No significant financial relationships to disclose.
Bacterial interference treatment of recurrent furunculosis. 2. Demonstration of the relationship of strain to pathogeneicity
Authors: W. G. Strauss
Journal: JAMA (1969)

Three patients with furunculosis due to a pathogenic strain of Staphylococcus aureus became free of furuncles after S aureus strain 502A was purposely substituted. Relapse of furunculosis occurred when 502A was lost and the original strain reacquired. Nine other patients lost their furuncles after replacement of a pathogenic strain by 502A. Abscess formation is a strain-related phenomenon in these patients, and disappearance of furuncles was not a chance event but was related to the implantation of strain 502A.
Perforation of Arteriosclerotic Aneurysms into the Inferior Vena Cava
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
RECENT TENDENCIES IN CHEMOTHERAPY
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
OTITIS MEDIA AND RUPTURE OF AMNIOTIC MEMBRANES
Journal: JAMA (1967)

Acute otitis media in the first hours and days of life has often been described by pathologists. And the clinical aspects were given concerted attention by Gomperz some 60 years ago in an investigation using the head mirror for ear examination.<sup>1</sup>More recently, in the<i>Archives of Otolaryngology</i>, clinical evidence has been reported which focuses attention once more on the problem.<sup>2</sup>In this study newborns in the nurseries of a large charity hospital were examined with the otoscope during the first week of life, and currently accepted signs of otitis media were found. Allowing for certain differences, the newborn ear is similar to that in the adult. On the first day the external canal and drum are obscured by creamy whitish material, apparently vernix caseosa, which can be irrigated away with a small-tipped medicine dropper and light mineral oil. By the fourth or fifth day the debris has